Construction of anti-cD20scFv/CD80/CD28/zeta recombinant gene modified T cell and research on its targeting cytotoxicity / 中华血液学杂志
Chinese Journal of Hematology
; (12): 111-114, 2007.
Article
de Zh
| WPRIM
| ID: wpr-328364
Bibliothèque responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To construct anti-CD20scFv/CD80/CD28/zeta recombinant gene modified T cells, test its effectiveness of eradicating CD20+ lymphoma cells and provide a probably new approach to tumor adoptive immunotherapy.</p><p><b>METHODS</b>CD28-zeta cDNA were amplified from vector pBULLET and inserted into pLNCX vector that contained anti-CD20scFv/CD80 gene. The recombinant vectors were transduced into PA317 cells and high titer retroviruses were obtained to infect human peripheral blood T lymphocytes. Resistant T cells were obtained by G418 selection at one week. Then transduced T lymphocytes and lymphoma cell lines Daudi Raji were cocultured. The cytotoxicity and cytokine production of transduced T cells were determined by non-radio-activation cytotoxicity assay and ELISA respectively.</p><p><b>RESULTS</b>The recombinant eukaryotic vector was constructed successfully as proved by enzyme digestion analysis and sequencing. These T cells were able to lyse CD20+ target cells and secrete high levels of IL-2 and IFN-gamma in vitro.</p><p><b>CONCLUSION</b>Recombinant gene modified T cells can be constructed successfully. It can specially kill CD20 positive lymphoma cells in vitro.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Plasmides
/
Lymphocytes T
/
Transfection
/
Lignée cellulaire
/
Immunothérapie adoptive
/
Antigène CD80
/
Antigène CD28
/
Antigènes CD20
/
Cytotoxicité immunologique
/
Allergie et immunologie
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Chinese Journal of Hematology
Année:
2007
Type:
Article